Psyence Biomedical Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBM research report →
Companywww.psyencebiomed.com
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.
- CEO
- Jody Aufrichtig
- IPO
- 2021
- Employees
- 12
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $76.27K
- P/E
- 2.25
- P/S
- 0.00
- P/B
- 0.34
- EV/EBITDA
- -5.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -47.61%
- ROIC
- -54.49%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $1.01M · 101.98%
- EPS
- $1.78 · 122.68%
- Op Income
- $-3,663,023
- FCF YoY
- -26.87%
Performance & Tape
- 52W High
- $468.36
- 52W Low
- $1.92
- 50D MA
- $4.45
- 200D MA
- $60.91
- Beta
- 1.79
- Avg Volume
- 2.68M
Get TickerSpark's AI analysis on PBM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PBM Coverage
We haven't published any research on PBM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PBM Report →